Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,524JPY
20 Oct 2017
Change (% chg)

¥12 (+0.79%)
Prev Close
¥1,512
Open
¥1,530
Day's High
¥1,531
Day's Low
¥1,518
Volume
6,745,300
Avg. Vol
7,089,876
52-wk High
¥1,688
52-wk Low
¥1,332

Select another date:

Wed, Oct 18 2017

Fitch Revises Beijing Capital Development's Outlook to Negative, Affirms Rating at 'BBB-'

(The following statement was released by the rating agency) HONG KONG, October 18 (Fitch) Fitch Ratings has revised Beijing Capital Development Holding (Group) Co., Ltd.'s (known by its abbreviated Chinese name Shokai Group) Outlook to Negative from Stable. Shokai Group's Long-Term Foreign-Currency Issuer Default Rating (IDR) has been affirmed at 'BBB-', and its senior unsecured rating and the ratings of all outstanding bonds have also been affirmed at 'BBB-'. A full list of rating actions is at

BRIEF-FDA grants fast track status to Astellas for acute myeloid leukemia drug

* U.S. FDA grants fast track designation to Astellas for development of gilteritinib in relapsed or refractory acute myeloid leukemia Source text for Eikon: Further company coverage:

BRIEF-Astellas and Seattle Genetics initiate trial of enfortumab vedotin for ureter cancer patients

* Astellas and Seattle Genetics initiate pivotal trial of Enfortumab Vedotin for patients with locally advanced or metastatic urothelial cancer

BRIEF-Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin

* Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer

BRIEF-Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial

* Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial

BRIEF-R&I affirms Astellas Pharma's rating at "AA" and says stable outlook-R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA"-R&I

CORRECTED-UPDATE 2-Pfizer, Astellas prostate cancer drug succeeds key trial

Sept 14 Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease.

Pfizer, Astellas prostate cancer drug clears late-stage trial

Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal in a late-stage trial.

CORRECTED-Pfizer, Astellas prostate cancer drug clears late-stage trial

Sept 14 Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial.

BRIEF-Astellas Pharma and Pfizer say positive top-line results from phase 3 prosper trial of XTANDI (enzalutamide)

* Co and Pfizer Inc announced that the Phase 3 PROSPER trial evaluating XTANDI®(enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic (M0) CastrationResistant Prostate Cancer (CRPC) met its primary endpoint of improved metastasis-free survival (MFS)

Select another date: